600 patients66,869 observations120 daysLIVE

Patient P-01325

Synthetic patientNBL-101 · Day 92 · 75+ · M · baseline S16Steering view · 3DOpen companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Improving
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
49%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 NBL-101 startedBaseline state S16
  2. Day 47 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 56 GI-04 recommendedGI Support Protocol GI-04
  4. Day 57 Patient acceptedStarted GI-04 in the companion
  5. Day 65 GI symptom burden −39% vs expectedGI Support Protocol GI-04
  6. Day 71 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 47.

Primary contributors, last 14 days
  • Toxicity+10
  • GI instability-4
  • Inflammatory activity+3
  • Treatment adherence-2

What helped?

  • GI Support Protocol GI-04Day 56
    Result: symptom burden −39%
LIFE OS recommendation
Dietary Support Protocol NP-02
51%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 66% showed improvement
  • median effect visible after 10 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden
Companion
41.5/100
worsening · +4.1 vs previous 14 d
Toxicity
Blood
49.4/100
worsening · +1.9 vs previous 14 d
Sleep quality
Wearable
24.7/100
stable · +0.2 vs previous 14 d
Energy level
Daily log
3.9/10
worsening · -0.6 vs previous 14 d
Stress level
Daily log
6.2/10
stable · +0.1 vs previous 14 d
Steps
Wearable
3,607
worsening · -189 vs previous 14 d
Adherence
Companion
56.9 %
worsening · -14.0 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 43 from the failing basin, 45 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 77 similar · onset 3 d · confidence 60%
  • NP-02 Dietary Support Protocol
    63% improved among 64 similar · onset 10 d · confidence 60%
  • SC-12 Supportive Compound
    76% improved among 51 similar · onset 6 d · confidence 60%
Would not help
  • Keep fat low
    GI +3.5 next day on high-intake days · n 26
  • Keep simple carbs low
    GI +2.8 next day on high-intake days · n 20
  • Keep histamine low
    GI +2.4 next day on high-intake days · n 17
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +3.5detractor · 95%
  • Simple carbohydrates
    +2.8detractor · 89%
  • Histamine load
    +2.4detractor · 82%
  • Alcohol
    +2.2detractor · 66%
  • Spicy / capsaicin
    +1.7no signal · 51%
  • Insoluble fibre
    -0.1no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 30/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 65
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 51
    • WearableHRV 23 ms, trending down
  • Autonomic recovery 65
    • WearableResting HR 73 bpm
    • Wearable3,607 steps/day
    • WearableShort sleep window
  • Drug metabolism and exposure 60
    • DNACYP2D6 poor metabolizer → higher exposure
    • BloodToxicity index 49
  • Mucosal barrier integrity 30
    • DNAFUT2 non-secretor lowers mucosal fucosylation
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Poor metabolizer
    Higher exposure at standard dose
Microbiome
Shannon diversity 2.3 · butyrate capacity 30/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
25 ms
Sleep
5.9 h
Steps
3,495
Resting HR
73 bpm
Daily log: GI score 42, nutritional resilience 41, adherence 57.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Protect a 7.5-hour sleep window; screens off 30 minutes before
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0180426%S19AD-05improved61
P-0144234%S13CR-01improved61
P-0169634%S20CR-01improved59
P-0137133%S06CR-01improved63
P-0183531%S17CR-01improved56
P-0170830%S07CR-01improved59
P-0138829%S17CR-01improved59
P-0187727%S01CR-01improved67
P-0143025%S05CR-01improved54
P-0176724%S14DT-01no change63
P-0166747%S10GI-04improved49
P-0134146%S14GI-04improved47